文献速递中医内科中药与中成药合理使用

代宗方通过调节肠道菌群改善db/db小鼠肝脏脂肪变性

Traditional Chinese Medicine formula Dai-Zong-Fang alleviating hepatic steatosis in db/db mice via gut microbiota modulation.
PubMed 文献 · Front Pharmacol · 2024-01-24

本研究以db/db小鼠为模型,探讨中药复方代宗方(DZF)基于肠-肝轴改善肝脏脂肪变性的机制。结果显示DZF可降低体重、改善糖脂代谢紊乱和胰岛素抵抗,降低血清AST和ALT,并调节肠道菌群多样性及功能,修复肠道屏障,减少内毒素血症,同时抑制肠道脂质吸收并改善肝脏脂质代谢,从而减轻肝脏脂肪变性。

要点

  • DZF可改善db/db小鼠糖脂代谢紊乱及胰岛素抵抗。
  • DZF调节肠道菌群,增加拟杆菌门丰度,修复肠道屏障。
  • DZF抑制肠道脂质吸收并改善肝脏脂质合成、摄取与氧化。

核心结论

  • DZF通过调节肠道菌群结构功能、修复肠道屏障、减轻内毒素血症,并抑制肠道脂质吸收、改善肝脏脂质代谢,从而减轻db/db小鼠肝脏脂肪变性。

研究设计与样本

  • 采用db/db小鼠作为疾病模型进行药物干预,监测体重和空腹血糖,检测血清脂质和转氨酶,进行胰岛素耐量试验,采用HE染色观察肝脏和肠道形态,油红O染色和肝脏脂质测定评估肝脏脂肪变性程度,16S rRNA基因测序评估肠道菌群变化,ELISA检测血清LPS,Western blot和RT-qPCR检测肠道紧密连接蛋白、肠道脂质吸收相关蛋白及肝脏脂质代谢关键蛋白表达。

主要发现

  • DZF干预后小鼠体重下降,糖脂代谢紊乱减轻,血清AST和ALT水平降低,胰岛素抵抗缓解。
  • DZF显著调节肠道菌群多样性,拟杆菌门丰度明显增加,PICRUSt提示DZF影响肠道菌群碳水化合物和氨基酸代谢等多种功能。
  • DZF干预后血清LPS水平降低,肠道病理损伤减轻,肠道紧密连接蛋白occludin表达增加,肠道脂质吸收相关蛋白CD36和ApoB48表达降低。
  • 肝脏中DZF干预减少肝脏脂肪变性和脂滴,伴随脂肪酸合酶(FASN)、硬脂酰辅酶A去饱和酶1(SCD1)和脂肪酸转运蛋白2(FATP2)表达降低,而脂肪酸氧化相关酶肉碱棕榈酰转移酶-1α(CPT-1α)表达增加。

临床怎么用

  • DZF可能通过调节肠道菌群、修复肠道屏障、抑制肠道脂质吸收及改善肝脏脂质代谢等多靶点作用,为代谢综合征相关肝脏脂肪变性的治疗提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Hepatic steatosis is a hepatic pathological change closely associated with metabolic disorders, commonly observed in various metabolic diseases such as metabolic syndrome (MetS), with a high global prevalence. Dai-Zong-Fang (DZF), a traditional Chinese herbal formula, is widely used in clinical treatment for MetS, exhibiting multifaceted effects in reducing obesity and regulating blood glucose and lipids. This study aims to explore the mechanism by which DZF modulates the gut microbiota and reduces hepatic steatosis based on the gut-liver axis. Methods: This study utilized db/db mice as a disease model for drug intervention. Body weight and fasting blood glucose were monitored. Serum lipid and transaminase levels were measured. Insulin tolerance test was conducted to assess insulin sensitivity. Hematoxylin and eosin (HE) staining was employed to observe morphological changes in the liver and intestine. The degree of hepatic steatosis was evaluated through Oil Red O staining and hepatic lipid determination. Changes in gut microbiota were assessed using 16S rRNA gene sequencing. Serum lipopolysaccharide (LPS) levels were measured by ELISA. The expression levels of intestinal tight junction proteins, intestinal lipid absorption-related proteins, and key proteins in hepatic lipid metabolism were examined through Western blot and RT-qPCR. Results: After DZF intervention, there was a decrease in body weight, alleviation of glucose and lipid metabolism disorders, reduction in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and mitigation of insulin resistance in mice. DZF significantly modulated the diversity of the gut microbiota, with a notable increase in the abundance of the Bacteroidetes phylum. PICRUSt indicated that DZF influenced various functions in gut microbiota, including carbohydrate and amino acid metabolism. Following DZF intervention, serum LPS levels decreased, intestinal pathological damage was reduced, and the expression of intestinal tight junction protein occludin was increased, while the expression of intestinal lipid absorption-related proteins cluster of differentiation 36 (CD36) and apolipoprotein B48 (ApoB48) were decreased. In the liver, DZF intervention resulted in a reduction in hepatic steatosis and lipid droplets, accompanied by a decrease fatty acid synthase (FASN) and stearoyl-CoA desaturase 1 (SCD1) and fatty acid transport protein 2 (FATP2). Conversely, there was an increase in the expression of the fatty acid oxidation-related enzyme carnitine palmitoyltransferase-1𝛂 (CPT-1𝛂). Conclusion: DZF can regulate the structure and function of the intestinal microbiota in db/db mice. This ameliorates intestinal barrier damage and the detrimental effects of endotoxemia on hepatic metabolism. DZF not only inhibits intestinal lipid absorption but also improves hepatic lipid metabolism from various aspects, including de novo lipogenesis, fatty acid uptake, and fatty acid oxidation. This suggests that DZF may act on the liver and intestine as target organs, exerting its effects by improving the intestinal microbiota and related barrier and lipid absorption functions, ultimately ameliorating hepatic steatosis and enhancing overall glucose and lipid metabolism.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang LW, Zhu LL, Zhu XY, et al. Traditional Chinese Medicine formula Dai-Zong-Fang alleviating hepatic steatosis in db/db mice via gut microbiota modulation. Front Pharmacol. 2024. PMID: 38327989. doi:10.3389/fphar.2024.1337057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。